EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Barinthus Biotherapeutics's Enterprise Value is €-24.23 Mil.
Barinthus Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-31.40 Mil. Therefore, Barinthus Biotherapeutics's EV-to-FCF for today is 0.77.
The historical rank and industry rank for Barinthus Biotherapeutics's EV-to-FCF or its related term are showing as below:
STU:2AB'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.2 Med: 0.93 Max: 6.16
Current: 0.74
During the past 7 years, the highest EV-to-FCF of Barinthus Biotherapeutics was 6.16. The lowest was -27.20. And the median was 0.93.
STU:2AB's EV-to-FCF is ranked better than 80.66% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs STU:2AB: 0.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Barinthus Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Barinthus Biotherapeutics's share price for today is €0.565.
Barinthus Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Barinthus Biotherapeutics EV-to-FCF Related Terms
Barinthus Biotherapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Barinthus Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's EV-to-FCF falls into.
Barinthus Biotherapeutics's current Enterprise Value is €-24.23 Mil.
Barinthus Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-31.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a EV-to-FCF of 0.77 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Barinthus Biotherapeutics and its competitors. This is 17% below median its historical median of 0.93. According to the industry distribution chart, Barinthus Biotherapeutics ranks #64 out of 331 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Barinthus Biotherapeutics' EV-to-FCF too high?
Barinthus Biotherapeutics' current EV-to-FCF of 0.77 is 17% below median its 10-year median of 0.93. The Biotechnology industry median EV-to-FCF is 15.90. Barinthus Biotherapeutics' value of 0.77 is 95.2% below this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #64 out of 331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' EV-to-FCF compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #64 out of 331 companies for EV-to-FCF. This places Barinthus Biotherapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.90. Barinthus Biotherapeutics' value of 0.77 is 95.2% below this benchmark. While the company's 10-year median is 0.93 vs. the industry median of 15.90, Barinthus Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current EV-to-FCF of 0.77 is 95.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current EV-to-FCF is 0.77, which is 17% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current EV-to-FCF of 0.77. The stock's GF Value™ is €0.94, compared to a current price of €0.57 — trading 39.9% below its estimated fair value. The current EV-to-FCF is 0.77, which is 17% below median its 10-year median of 0.93 and 95.2% below the Biotechnology industry median of 15.90. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current EV-to-FCF is 0.77 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.57 is trading 39.9% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
EV-to-FCF: 0.77 (17% below median its 10-year median of 0.93)
GF Value™: €0.94 vs. price of €0.57 (39.9% below fair value)
Industry Position: 95.2% below the Biotechnology median (#64 of 331)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
